Economic burden of osteoporosis in India among treated populations (ECON-OP): a prevalence-based cost-of-illness analysis across key risk groups

Lakshmi Nagendra; Yogesh Sharma

doi:10.18203/issn.2455-4510.IntJResOrthop20263935

Authors

Lakshmi Nagendra Department of Endocrinology, JSS Medical College, JSS Academy of Higher Education and Research, Mysore, Karnataka, India https://orcid.org/0000-0001-6865-5554
Yogesh Sharma Medical Affairs, Abbott Healthcare Pvt. Ltd., Mumbai, Maharashtra, India

DOI:

https://doi.org/10.18203/issn.2455-4510.IntJResOrthop20263935

Keywords:

Osteoporosis, Cost-of-illness, Economic burden, Fragility fractures, India, Glucocorticoid-induced osteoporosis

Abstract

Background: Osteoporosis is a major public health concern in India, leading to fractures, disability, and increased healthcare utilization. However, evidence on its economic burden in the Indian setting remains limited. This study estimated the economic burden of osteoporosis among treated patients in India and evaluated differences between primary and secondary prevention populations.

Methods: A prevalence-based cost-of-illness model was developed for postmenopausal women (PMO), men aged ≥50 years, and patients with glucocorticoid-induced osteoporosis (GIOP). The analysis included treated patients only and applied a weighted healthcare cost mix of 70% public and 30% private sector utilization. Costs were estimated from payer and societal perspectives and reported in Indian Rupees (INR).

Results: The total annual societal economic burden among treated patients was estimated at INR 22,773.6 crores, comprising INR 16,226.5 crores for PMO, INR 6,057.3 crores for male osteoporosis, and INR 489.7 crores for GIOP. Direct medical costs were the major contributor across all populations. Per-patient costs were substantially higher among fracture patients than non-fracture patients, reaching INR 2.15 versus 0.30 lakhs in PMO, INR 2.29 versus 0.35 lakhs in men, and INR 2.16 versus 0.34 lakhs in GIOP. Fracture-related costs were approximately seven-fold higher than costs in primary prevention populations. Scenario analyses suggested a markedly greater burden associated with untreated osteoporosis.

Conclusions: Osteoporosis imposes a substantial economic burden in India, driven primarily by fracture-related costs. Early diagnosis, sustained treatment, and effective fracture prevention strategies may substantially reduce healthcare expenditure and societal burden.

References

Clynes MA, Harvey NC, Curtis EM, Fuggle NR, Dennison EM, Cooper C. The epidemiology of osteoporosis. Br Med Bull. 2020;133(1):105-17.

Borgström F, Karlsson L, Ortsäter G, Norton N, Halbout P, Cooper C, et al. Fragility fractures in Europe: burden, management and opportunities. Arch Osteoporos. 2020;15(1):59.

Agrawal AC, Garg AK. Epidemiology of osteoporosis. Indian J Orthop. 2023;57(Suppl 1):45-8.

Sözen T, Özışık L, Başaran NÇ. An overview and management of osteoporosis. Eur J Rheumatol. 2017;4(1):46-56. doi: 10.5152/eurjrheum.2016.048.

Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, et al. The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res. 2021;16(1):609.

Dhanwal DK, Sahoo S, Gautam VK, Saha R. Hip fracture patients in India have vitamin D deficiency and secondary hyperparathyroidism. Osteoporos Int. 2013;24(2):553-7.

Khadilkar AV, Mandlik RM. Epidemiology and treatment of osteoporosis in women: an Indian perspective. Int J Womens Health. 2015;7:841-50.

Khinda R, Valecha S, Kumar N, Walia JPS, Singh K, Sethi S, et al. Prevalence and predictors of osteoporosis and osteopenia in postmenopausal women of Punjab, India. Int J Environ Res Public Health. 2022;19(5):2999.

Mehta N, Garg B, Malhotra R. Management of fragility fractures in India. Best Pract Res Clin Rheumatol. 2019;33(2):301-9.

Bandeira L, Silva BC, Bilezikian JP. Male osteoporosis. Arch Endocrinol Metab. 2022;66(5):739-47.

De Martinis M, Sirufo MM, Polsinelli M, Ginaldi L. Gender differences in osteoporosis: a single-center observational study. World J Mens Health. 2021;39(4):750-9.

Ilias I, Milionis C, Zoumakis E. An overview of glucocorticoid-induced osteoporosis. In: Feingold KR, Ahmed SF, Anawalt B, et al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK278968/ Accessed on 10 August 2026.

Weinstein RS. Glucocorticoid-induced osteoporosis and osteonecrosis. Endocrinol Metab Clin North Am. 2012;41(3):595-611.

Humphrey MB, Russell L, Danila MI, Gavigan K, Humphrey H, Pace CA, et al. 2022 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Rheumatol. 2023;75(12):2088-102.

Rashki Kemmak A, Rezapour A, Jahangiri R, Nikjoo S, Farabi H, Soleimanpour S. Economic burden of osteoporosis in the world: a systematic review. Med J Islam Repub Iran. 2020;34:154.

Balkhi B, Alshehri N. Evaluating the economic burden of osteoporosis in the United States: insights from a MEPS-based analysis. Value Health. 2023;26(Suppl 12).

Mithal A, Bansal B, Kyer CS, Ebeling P. The Asia-Pacific regional audit: epidemiology, costs, and burden of osteoporosis in India 2013. Indian J Endocrinol Metab. 2014;18(4):449-54.

Carlos-Rivera F, Guzmán-Caniupan JA, Camacho-Cordero LM, et al. Estimated frequency and economic burden of incident fragility fractures during 2023 in Mexico. Arch Osteoporos. 2024;19(1):109.

Svedbom A, Ivergård M, Hernlund E, Rizzoli R, Kanis JA. Epidemiology and economic burden of osteoporosis in Switzerland. Arch Osteoporos. 2014;9:187.

Marcellusi A, Rotundo MA, Nardone C, Viti R, Di Marco M, Sessa M, et al. Osteoporosis: economic burden of disease in Italy. Clin Drug Investig. 2020;40(5):449-58.

Schnitzler L, Roberts TE, Jackson LJ, Paulus ATG, Evers SMAA. A consensus-based checklist for the critical appraisal of cost-of-illness studies. Int J Technol Assess Health Care. 2023;39(1).

Liang H, Chen S, Shi M, Xu J, Zhao C, Yang B, et al. Global epidemiology and burden of osteoporosis among postmenopausal women: insights from the Global Burden of Disease Study 2021. NPJ Aging. 2025;11(1):78. doi: 10.1038/s41514-025-00269-2.

Tai TW, Lin YH, Chang CJ, Wu CH. The economic burden of hip fractures in Asia. Osteoporos Sarcopenia. 2021;7(2):45-6.

Cheung CL, Ang SB, Chadha M, Chow ES, Chung YS, Hew FL, et al. An updated hip fracture projection in Asia: the Asian Federation of Osteoporosis Societies study. Osteoporos Sarcopenia. 2018;4(1):16-21.

Madhusudan S, Misra A. Osteoporosis in India: a public health perspective. Curr Med Res Pract. 2012;2(2):71-2.

Sopina L, Hitz MF, Thygesen LC, Langdahl B, Ladefoged BT, Kruse M. Healthcare and productivity cost of osteoporosis: a Danish register-based quasi-experimental study. Osteoporos Int. 2025;36(5):865–74.

Varthakavi PK, Joshi AS, Bhagwat NM, Chadha MD. Osteoporosis treatment in India: call for action. Indian J Endocrinol Metab. 2014;18(4):441-2.

Rath S, Yadav L, Tewari A, Sood A, Majumdar S, Gupta S, et al. Management of older adults with hip fractures in India: a mixed methods study of current practice, barriers and facilitators, with recommendations to improve care pathways. Arch Osteoporos. 2017;12(1):55.